Former Novartis execs launch new investment fund Aditum and set up Tempero Bio with Sosei

2 November 2020

Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis chief executive Joe Jimenez and former president of the Novartis Institutes for BioMedical Research (NIBR) Dr Mark Fishman, today announced the formation of Tempero Bio, a portfolio company developing a new neuroscience drug for the treatment of substance use disorders and anxiety, often neglected fields in drug development, to help address significant treatment gaps for patients.

Tempero Bio is being formed in partnership with Japan’s Sosei Heptares (TYO: 4565), the company from which the drug TMP-301 was in-licensed. Tempero Bio has in-licensed exclusive global rights to Sosei Heptares’ mGlu5 negative allosteric modulator (NAM) program to develop therapies targeting substance use disorders and anxiety.

Under the terms of the agreement, Tempero Bio will obtain exclusive global rights to a portfolio of potent, orally available metabotropic glutamate receptor 5 (mGlu5) NAM modulators, including HTL0014242, which were precision-designed by Sosei Heptares using its GPCR structure-based drug eesign (SBDD) platform. The candidate HTL0014242 has been renamed TMP-301.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK